
Tirzepatide tops India’s GLP-1 market with 62% share
The story in brief
Injectable tirzepatide and semaglutide, launched in 2025, have dominated India’s GLP-1 market, with tirzepatide accounting for Rs 1,456 crore (62%) and semaglutide contributing Rs 782 crore (34%). The market is stabilizing after a surge driven by generics, which made the drugs more affordable.